News · Clinical trials

SYNCHRONIZE-1: 16.6% Weight Loss With 34% Less Visceral Fat and 63% Less Liver Fat

A 76-week phase 3 readout measuring where fat is lost, not only how much — which is the more clinically informative question.

Event date 2026-06-11 · Published 2026-07-24 · EV-0813

What was measured

SYNCHRONIZE-1, a 76-week phase 3 trial, reported 16.6% weight loss alongside a 34% reduction in visceral fat and a 63% reduction in liver fat.

The fat-distribution measures are the interesting part. Total weight is what patients see and what marketing quotes. Visceral and hepatic fat are what drive metabolic risk, and they do not move in lockstep with the scale.

Why distribution matters more than magnitude

Subcutaneous fat is metabolically comparatively inert. Visceral fat — around the abdominal organs — is associated with insulin resistance, inflammation and cardiovascular risk. Hepatic fat is the substrate of metabolic dysfunction-associated steatotic liver disease, which progresses in some patients to fibrosis and cirrhosis.

A 63% reduction in liver fat is therefore a more clinically loaded number than the 16.6% weight figure beside it, and it is the one least likely to appear in a headline.

Where this connects to the lean-mass debate

The counterpart concern to fat distribution is lean mass. Body-composition analyses put the lean-mass share of total weight loss on high-efficacy GLP-1s at roughly 20% to 40%, and a phase 2 trial combining semaglutide with the myostatin inhibitor bimagrumab reduced that fraction from about 21% to 7%.

Together these point at the same conclusion: total weight change is a crude measure. What is lost, and from where, determines whether the intervention improves health or merely reduces a number — and almost no consumer-facing comparison in this market measures either.

What it does not establish

That fat redistribution translates into clinical outcomes. Reduced liver fat is a surrogate for reduced liver disease progression, and surrogates in hepatology have a mixed record. Outcome trials with fibrosis endpoints are a different and longer undertaking.

It also says nothing about compounded preparations, microdoses or oral formulations, none of which appear in body-composition or imaging trials.

What a patient can take from it

Two questions worth raising with a clinician. Whether your assessment includes anything beyond weight — waist circumference, liver function, glycaemic markers. And whether the treatment target is a number on a scale or a metabolic parameter, because those can diverge.

A programme measuring only weight is measuring the least informative available variable, and most telehealth models measure nothing else.

Questions readers actually ask

Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.